GLS and renal cell carcinoma: Therefore, a variety of glutaminase (GLS) inhibitors are under investigation, among which BPTES is one of the promising GLS inhibitors that efficiently increased the sensitivity of pancreatic cancer cells to a couple of therapies, and in renal cell carcinoma, another GLS inhibitor, known as CB‐839, is considered a potential drug.145